Organization Overview
Alternative names
aprepitant (Emend) (2021)
fulvestrant (faslodex) (2020)
abiraterone (zytiga) (3 trials)
anastrozole (arimidex) (1 trial)
antihemophilic factor viii human (Hemofil M) (1 trial)
antihemophilic factor viii (Recombinant) (Adynovate) (2 trials)
bevacizumab (avastin) (4 trials)
capecitabine (xeloda) (9 trials)
cisplatin (platinol) (14 trials)
coagulation factor viia (recombinant) (NovoSevenRT) (2 trials)
ethinyl estradiol (Estinyl) (1 trial)
etoposide (vepesid) (2 trials)
faropenem medoxomil (Fropenem) (2 trials)
fluorouracil (efudex) (2 trials)
fluticasone (cutivate) (1 trial)
fulvestrant (faslodex) (5 trials)
gemcitabine (gemzar) (7 trials)
ibrutinib (imbruvica) (2 trials)
metformin (glucophage) (1 trial)
methylnaltrexone (relistor) (1 trial)
obeticholic acid (ocaliva) (2 trials)
paclitaxel (taxol) (14 trials)
palbociclib (ibrance) (9 trials)
pembrolizumab (keytruda) (1 trial)
pemetrexed (alimta) (8 trials)
pertuzumab (perjeta) (1 trial)
albuterol (proventil) (1 trial)
bendamustine (treanda) (1 trial)
caspofungin (cancidas) (1 trial)
efgbemalenograstim alfa (1 trial)
hydroxyurea (hydrea) (1 trial)
linagliptin (tradjenta) (1 trial)
osimertinib (tagrisso) (2 trials)
pirfenidone (esbriet) (1 trial)
roflumilast (daliresp) (1 trial)
Adenocarcinoma (Phase 3)
Agranulocytosis (Phase 2)
Asthma (Phase 3)
Bone Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Neuroendocrine (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 4)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Squamous Cell (Phase 3)
Chemical and Drug Induced Liver Injury (Phase 2)
Cholangiocarcinoma (Phase 2)
Colonic Diseases (Phase 2)
Colorectal Neoplasms (Phase 4)
Constipation (Phase 3)
Diabetes Mellitus (Phase 3)
Diabetes Mellitus, Type 2 (Phase 3)
Digestive System Diseases (Phase 2)
Digestive System Neoplasms (Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 2)
Fibrosis (Phase 2)
Gastrointestinal Diseases (Phase 2)
Gastrointestinal Neoplasms (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
Healthcare-Associated Pneumonia (Phase 2)
Hematologic Neoplasms (Phase 1)
Hemophilia A (Phase 3)
Hepatitis (Phase 4)
Hepatitis A (Phase 4)
Hepatitis B (Phase 4)
Hepatitis B, Chronic (Phase 4)
Hepatitis, Chronic (Phase 4)
Herpes Zoster (Phase 4)
Hodgkin Disease (Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 2)
Inflammation (Phase 4)
Intestinal Diseases (Phase 2)
Intestinal Neoplasms (Phase 2)
Kidney Neoplasms (Phase 3)
Leukemia (Phase 4)
Leukemia, Myeloid (Phase 4)
Liver Cirrhosis (Phase 2)
Liver Cirrhosis, Biliary (Phase 2)
Lung Diseases, Obstructive (Phase 2)
Lung Neoplasms (Phase 4)
Lymphohistiocytosis, Hemophagocytic (Phase 1)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 3)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Melanoma (Phase 2)
Multiple Myeloma (Phase 1)
Mycoses (Phase 2)
Myelodysplastic Syndromes (Phase 4)
Myeloproliferative Disorders (Phase 1)
Nasopharyngeal Carcinoma (Phase 3)
Nausea (Phase 4)
Neoplasms (Phase 3)
Neoplasms by Site (Phase 2)
Neuroendocrine Tumors (Phase 2)
Osteoporosis (Phase 4)
Osteoporosis, Postmenopausal (Phase 4)
Pancreatic Neoplasms (Phase 2)
Pneumonia (Phase 3)
Pneumonia, Bacterial (Phase 3)
Preleukemia (Phase 4)
Prostatic Neoplasms (Phase 3)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Pulmonary Fibrosis (Phase 2)
Rectal Diseases (Phase 2)
Recurrence (Phase 2)
Sarcoma (Phase 3)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stomach Neoplasms (Phase 3)
Syndrome (Phase 4)
Thyroid Diseases (Phase 3)
Thyroid Neoplasms (Phase 3)
Triple Negative Breast Neoplasms (Phase 3)
Urologic Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Vomiting (Phase 4)
Wounds and Injuries (Phase 4)
